Journal of Clinical Pediatrics ›› 2023, Vol. 41 ›› Issue (9): 686-691.doi: 10.12372/jcp.2023.22e1634

• General Report • Previous Articles     Next Articles

Analysis of prognostic factors and survival status of group 4 medulloblastoma in children

WU Yuefang, SUN Yanling(), WU Wanshui, DU Shuxu, LI Miao, SUN Liming   

  1. Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
  • Received:2022-12-06 Online:2023-09-15 Published:2023-09-05
  • Contact: SUN Yanling


Objective To investigate the survival status and prognostic factors of group 4 medulloblastoma (MB) in children. Methods The clinical data of children with group 4 MB admitted to the Department of Pediatrics from May 2016 to August 2020 (follow-up until August 2022) were retrospectively analyzed. The Kaplan-Meier method was used to calculate the overall survival (OS) rate and progression-free survival (PFS) rate. Log-rank test was used to compare the difference in survival rate between groups, and Cox regression model was used to analyze the factors affecting prognosis. Results A total of 145 children (106 boys and 39 girls) with group 4 MB were included, and the median age of diagnosis was 7.5 (5.7-9.6) years old. There were 91 children in M0 stage and 54 children in M+ stage (1 in M1 stage, 12 in M2 stage and 41 in M3 stage). The pathologic types were classic in 127 cases, desmoplastic/nodular (DN) in 8 cases, anaplastic/large cell (LC/A) in 8 cases, extensive nodularity (EN) in 1 case, and none of somatotype (NOS) in 1 case. The median follow-up time was 47.9 (36.5-59.3) months, and 37 children had tumor recurrence. The 5-year OS and PFS rates were (80.8±3.4) % and (55.4±4.7) %, respectively. Cox regression analysis indicated that M+ stage, MYCN amplification and Chr12p+ variation were independent risk factors for prognosis (P<0.05). Conclusions Group 4 MB children with M+ stage or MYCN amplification have a relatively poor prognosis. Chr12p + may be related to the prognosis of children, but it needs to be confirmed by clinical studies with larger samples.

Key words: group 4 medulloblastoma, prognosis, influencing factor, child